BioNTech SE Sponsored ADR $BNTX Shares Sold by Flossbach Von Storch SE

Key Points

• Flossbach Von Storch SE trimmed its BioNTech stake by 0.8% in Q4, selling 33,985 shares and now holds about 4,196,048 shares worth roughly $399.5 million, making BNTX its 21st largest holding.
• COO Sierk Poetting sold 50,000 shares on April 22 under a Rule 10b5-1 plan at an average of $110.56 for about $5.53 million, reducing his ownership by ~11.13%; insiders collectively own 19.20% of the company.
• Analyst consensus is a Moderate Buy with an average price target of $133.13 (1 Strong Buy, 12 Buy, 4 Hold, 1 Sell); the stock trades near $102 with a 1‑year range of $79.52–$124 and a market cap of $25.81 billion.

Flossbach Von Storch SE decreased its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 0.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,196,048 shares of the company's stock after selling 33,985 shares during the quarter. BioNTech accounts for about 1.6% of Flossbach Von Storch SE's holdings, making the stock its 21st biggest holding. Flossbach Von Storch SE owned 1.86% of BioNTech worth $399,464,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in BNTX. Royal Bank of Canada increased its position in shares of BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company's stock valued at $653,000 after purchasing an additional 3,514 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of BioNTech during the 1st quarter worth $167,000. Russell Investments Group Ltd. grew its stake in shares of BioNTech by 368,800.0% during the second quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company's stock worth $1,178,000 after purchasing an additional 11,064 shares in the last quarter. Natixis acquired a new position in shares of BioNTech during the second quarter worth $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in BioNTech by 2.9% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company's stock valued at $52,416,000 after buying an additional 13,788 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

Insider Buying and Selling

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the business's stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the sale, the chief operating officer owned 399,387 shares in the company, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of analyst reports. The Goldman Sachs Group restated a "buy" rating on shares of BioNTech in a research note on Wednesday, March 11th. Leerink Partners cut BioNTech from an "outperform" rating to a "market perform" rating and set a $113.00 price objective for the company. in a research report on Monday, February 2nd. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.00 price objective on shares of BioNTech in a report on Wednesday, March 11th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of BioNTech in a research report on Tuesday, March 17th. Finally, Bank of America reaffirmed a "buy" rating and issued a $128.00 price target on shares of BioNTech in a report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $133.13.

BioNTech Stock Performance

NASDAQ BNTX opened at $102.06 on Tuesday. The company has a fifty day moving average of $97.89 and a two-hundred day moving average of $101.12. The company has a market capitalization of $25.81 billion, a PE ratio of -19.48 and a beta of 1.58. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The firm had revenue of $1.06 billion during the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. As a group, analysts expect that BioNTech SE Sponsored ADR will post -4.41 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.